Survival according to CI. (A) Patients treated with total therapy II who had a high CI had significantly shorter OS than those with low CI (median survival, 42.7 months vs not yet reached, log-rank P < .0001). (B) The OS of patients with PI greater than 2 from the UAMS dataset is further dichotomized by CI levels (median OS of high CI vs low CI is 30.6 months vs 45.6 months, log-rank P = .04). Patients entered into bortezomib trials with a high CI had significantly shorter (C) OS (median survival, 11.5 months vs 20.9 months, log-rank P = .0002) and (D) PFS (median, PFS 2.8 months vs 4.9 months, log-rank P = .02) than those with low CI.